argenx NV ADR share price logo

argenx NV ADR Share Price

NASDAQ: ARGX

Large Cap

$834.80

-14.24

(-1.68%)

as on

argenx NV ADR Stock Performance

as on April 21, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $831.43
    $847.20
    downward going graph

    0.40%

    Downside

    1.49%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $510.06
    $934.62
    downward going graph

    38.90%

    Downside

    11.96%

    Upside

    downward going graph

argenx NV ADR share price movements today

Previous Close
$849.04
Open
$847.20
Volume
205.8K
Day's Low - High
$831.43 - $847.20
52 Week Low - High
$510.06 - $934.62

argenx NV ADR Historical Returns

1 Month Return
+ 27.88 %
3 Month Return
+ 4.87 %
1 Year Return
+ 42.41 %
3 Year Return
+ 123.43 %
5 Year Return
+ 205.04 %

argenx NV ADR Stock Fundamentals & Key Indicators

Check argenx NV ADR market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$53.1B

EPS (TTM)

21.4277

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.32%

PE Ratio (TTM)

43.3

Industry PE ratio

-9.801875

PEG Ratio

1.3362

EBITDA

1.1B

Revenue (TTM)

4.2B

Profit Margin

30.50%

Return On Equity TTM

20.15%

argenx NV ADR Stock Valuation

Track how argenx NV ADR P/E has moved over time to understand its valuation trends.

argenx NV ADR in the last 5 years

  • Overview

  • Trends

Lowest (-112.45x)

September 30, 2023

Industry (-9.80x)

April 20, 2026

Today (43.30x)

April 20, 2026

Highest (130.78x)

March 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 43.30x

argenx NV ADR vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of argenx NV ADR with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
argenx NV ADR image
argenx NV ADR
BUY$53.1B205.04%43.330.50%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$41.3B127.64%133.478.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$112.2B100.4%28.8232.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$37.2BNA131.655.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$79.4B48.8%18.0831.41%

Stock Returns calculator for argenx NV ADR Stock including INR - Dollar returns

The argenx NV ADR stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

argenx NV ADR investment value today

Current value as on today

₹1,53,051

Returns

₹53,051

(+53.05%)

Returns from argenx NV ADR Stock

₹40,020 (+40.02%)

Dollar Impact

₹13,031 (+13.03%)

Analyst Recommendation on argenx NV ADR Stock

Based on 25 analysts

BUY

72.00%

Buy

24.00%

Hold

4.00%

Sell

Based on 25 analysts, 72% of analysts recommend a 'BUY' rating for argenx NV ADR. Average target price of $1035.28

argenx NV ADR Share Price Target

Get share price movements and forecasts by analysts on argenx NV ADR.

What analysts predicted

19.36%UPSIDE

Target Price

$1035.28

Current Price

$834.8

Analyzed by

25 Analysts

Target

$1035.28

argenx NV ADR target price $1035.28, a slight upside of 19.36% compared to current price of $834.8. According to 25 analysts rating.

argenx NV ADR Stock’s Investor Sentiment and Interest

Search interest for argenx NV ADR Stock has decreased by -45% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-45% versus previous 30 day period

argenx NV ADR Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
352
826
401
970
636
1,346
790
947
1,126
2,406
Gross Profit
313
200
357
1,379
570
681
709
837
1,017
2,147
Operating Income
-80
-219
-93
-138
14
117
138
201
349
658
EBITDA
-83
-38
-73
-21
88
126
203
513
-
789
Interest Expense
0
0
0
0
0
0
1
1
0
1
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-83
-144
-74
-89
88
174
202
286
386
787
Income Tax Expense
-10
27
-12
-56
-3
-687
32
41
-
-87
Net Income
-77
-169
-61
-35
101
865
169
245
344
874
Net Profit Margin
-22.03%
-20.54%
-15.36%
-3.61%
15.95%
64.29%
21.43%
25.88%
30.55%
36.36%

argenx NV ADR Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
16
51
27
87
50
562
434
1,337
2,190
4,164
Gross Profit
16
51
27
87
50
562
403
1,209
1,962
3,712
Operating Income
-22
-27
-93
-198
-477
-348
-720
-425
-21
972
EBITDA
-22
-32
-93
-173
-601
-392
-622
-192
105
972
Interest Expense
-
5
35
0
0
1
2
0
2
4
Depreciation
-
0
0
2
3
5
104
111
17
28
Income Before Tax
-22
-32
-75
-175
-605
-399
-729
-304
85
1,282
Income Tax Expense
0
0
0
5
3
8
-19
-9
-747
-13
Net Income
-23
-39
-86
-201
-740
-460
-750
-321
833
1,296
Net Profit Margin
-145.27%
-77.10%
-310.22%
-230.95%
-1475.29%
-81.97%
-172.76%
-24.06%
38.03%
31.12%

argenx NV ADR Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-155
-57
-32
84
865
149
418
295
874
Operating Cash Flow
-134
-
-124
-
41
-
437
-
407
Investing Cash Flow
-218
-
-513
-
-203
-
-10
-
829
Financing Cash Flow
1,274
-
40
-
239
-
74
-
158
Change in Cash
938
-
-610
-
61
-
586
-
1,405

argenx NV ADR Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-27
-93
-198
-477
-348
-720
-425
833
1,296
Operating Cash Flow
-43
-61
151
-398
-606
-862
-420
-82
850
Investing Cash Flow
-194
-123
-833
344
-347
-461
308
-717
823
Financing Cash Flow
366
279
733
833
1,119
843
1,336
279
233
Change in Cash
121
103
50
844
117
-533
1,248
-548
1,991

Mutual Funds that own argenx NV ADR Stock

Check out the Mutual Funds with significant holdings in argenx NV ADR.

Global Institutional Holdings in argenx NV ADR

Funds
Holdings
ClearBridge Advisors, LLC
0.83%
Citadel Advisors Llc
0.57%
Bank of America Corp
0.55%
SEI Investments Co
0.5%
venBio Select Advisor LLC
1.6%
See all

argenx NV ADR News & Key Events

  • img

    Today's Timeline - 26 February

    Thu, 06:09 PM

    -

    Argenx reports strong 2025 results, achieving $4.15 billion in global product net sales and first profitable year.

Insights on argenx NV ADR

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Argenx SE has shown strong profit growth over the last four quarters. The net profit increased from $169.46 million to $874.91 million, reflecting an average growth of 40.1% each quarter.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Argenx SE has shown strong revenue growth over the last four quarters. The company's revenue increased from $790.68 million to $2.40 billion, reflecting an average rise of 28.6% each quarter.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ARGX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, ARGX stock has moved up by 27.9%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ARGX has outperformed top 5 stocks with highest market-cap in its industry

About argenx NV ADR

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Organisationargenx NV ADR
HeadquartersLaarderhoogtweg 25, Amsterdam, Netherlands, 1101 EB
IndustryBiotechnology
CEOMr. Timothy Van Hauwermeiren EMBA, M.Sc.
E-voting on sharesClick here to vote

Key Management of argenx NV ADR

Name

Title

Ms. Malini Moorthy

General Counsel & Corporate Secretary

Mr. Arjen Lemmen M.Sc.

Vice President of Corporate Development & Strategy

Ms. Andria Wilk

Global Head of Quality

Dr. Luc Truyen

Chief Medical Officer

Prof. Hans de Haard Ir, Ph.D.

Co-Founder & Member of Board Advisors

Mr. Timothy Van Hauwermeiren EMBA, M.Sc.

Co-Founder, CEO & Executive Director

Mr. Karl Gubitz

Chief Financial Officer

Ms. Karen Massey

Chief Operating Officer

Dr. Peter Ulrichts

Chief Scientific Officer

Mr. Filip Borgions

Chief Technology Innovation Officer

FAQs

What is argenx NV ADR share price today?

argenx NV ADR share price today is $834.8 as on at the close of the market. argenx NV ADR share today touched a day high of $847.2 and a low of $831.43.

What is the 52 week high and 52 week low for argenx NV ADR share?

argenx NV ADR share touched a 52 week high of $934.62 on and a 52 week low of $510.06 on . argenx NV ADR stock price today i.e. is closed at $834.8,which is 10.68% down from its 52 week high and 63.67% up from its 52 week low.

What is argenx NV ADR's market capitalisation today?

argenx NV ADR market capitalisation is $0.05T as on .

How to invest in argenx NV ADR Stock (ARGX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for argenx NV ADR on INDmoney app. Click on Buy button. You can invest as low as $1.5 in argenx NV ADR Shares that will get you 0.0018 shares as per argenx NV ADR share price of $834.8 per share as on April 21, 2026 at 1:29 am IST.

What is the minimum amount required to buy argenx NV ADR Stock (ARGX) from India?

Indian investors can start investing in argenx NV ADR (ARGX) shares with as little as ₹93.107 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹931.07 in argenx NV ADR stock (as per the Rupee-Dollar exchange rate as on ). Based on argenx NV ADR share’s latest price of $834.8 as on April 21, 2026 at 1:29 am IST, you will get 0.0120 shares of argenx NV ADR. Learn more about fractional shares .

What are the returns that argenx NV ADR has given to Indian investors in the last 5 years?

argenx NV ADR stock has given 205.04% share price returns and 22.82% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?